The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet

By Marchand Christophe  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 901-904

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

By Ramanathan Srinivasan   Mathias Anita A.   German Polina   Kearney Brian P.  

Clinical Pharmacokinetics, Vol. 50, Iss. 4, 2011-04 ,pp. : 229-244

Adis International

Access to resources Recommend Favorite

Raltegravir: an integrase inhibitor for HIV-1

By Evering Teresa H   Markowitz Martin  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 413-422

Informa Healthcare

Access to resources Recommend Favorite

Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile

By Gianotti Nicola   Lazzarin Adriano  

Future Virology, Vol. 2, Iss. 2, 2007-03 ,pp. : 131-143

Future Medicine

Access to resources Recommend Favorite

Meta-analysis of once-daily and twice-daily lopinavir/ritonavir combined with NRTIs in HIV-1-infected, antiretroviral-naive patients

By van Wyk Jean   Qaqish Roula   Hollar Kimberly   White Kelly   D’’Amico Ronald   Norton Michael   Chiu Yi-Lin   King Martin  

Future Virology, Vol. 7, Iss. 1, 2012-01 ,pp. : 103-113

Future Medicine

Access to resources Recommend Favorite